Aurinia Pharmaceuticals Inc (AUPH): Price and Financial Metrics


Aurinia Pharmaceuticals Inc (AUPH): $4.60

-0.05 (-1.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AUPH POWR Grades

  • Growth is the dimension where AUPH ranks best; there it ranks ahead of 78.37% of US stocks.
  • AUPH's strongest trending metric is Value; it's been moving up over the last 26 weeks.
  • AUPH's current lowest rank is in the Stability metric (where it is better than 1.14% of US stocks).

AUPH Stock Summary

  • The ratio of debt to operating expenses for AURINIA PHARMACEUTICALS INC is higher than it is for about just 8.49% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.14 for AURINIA PHARMACEUTICALS INC; that's greater than it is for just 10.41% of US stocks.
  • Revenue growth over the past 12 months for AURINIA PHARMACEUTICALS INC comes in at 78.59%, a number that bests 89.28% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to AUPH, based on their financial statements, market capitalization, and price volatility, are UDMY, ADN, USER, DMTK, and BIOC.
  • AUPH's SEC filings can be seen here. And to visit AURINIA PHARMACEUTICALS INC's official web site, go to www.auriniapharma.com.

AUPH Valuation Summary

  • In comparison to the median Healthcare stock, AUPH's price/sales ratio is 12.5% higher, now standing at 5.4.
  • AUPH's price/sales ratio has moved down 118.9 over the prior 100 months.

Below are key valuation metrics over time for AUPH.

Stock Date P/S P/B P/E EV/EBIT
AUPH 2022-12-05 5.4 1.6 -6.0 -5.4
AUPH 2022-12-02 5.6 1.7 -6.3 -5.7
AUPH 2022-12-01 5.6 1.7 -6.2 -5.6
AUPH 2022-11-30 5.7 1.7 -6.3 -5.7
AUPH 2022-11-29 5.5 1.7 -6.1 -5.5
AUPH 2022-11-28 5.4 1.6 -6.0 -5.4

AUPH Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at -199.52%.
  • Its year over year cash and equivalents growth rate is now at -15.36%.
  • Its 2 year net income to common stockholders growth rate is now at -31.47%.
AUPH's revenue has moved up $128,681,000 over the prior 33 months.

The table below shows AUPH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 128.999 -115.901 -115.456
2022-06-30 87.887 -140.789 -156.722
2022-03-31 66.316 -150.897 -168.217
2021-12-31 45.605 -157.692 -180.966
2021-09-30 72.231 -126.313 -170.2
2021-06-30 57.593 -116.343 -154.009

AUPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AUPH has a Quality Grade of D, ranking ahead of 9.07% of graded US stocks.
  • AUPH's asset turnover comes in at 0.178 -- ranking 206th of 682 Pharmaceutical Products stocks.
  • SVRA, SESN, and VSTM are the stocks whose asset turnover ratios are most correlated with AUPH.

The table below shows AUPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.178 0.992 -0.759
2021-06-30 0.133 0.994 -0.753
2021-03-31 0.125 0.999 -0.874
2020-12-31 0.131 1.000 -1.010
2020-09-30 0.000 1.000 -2.541
2020-06-30 0.001 1.000 -10.800

AUPH Price Target

For more insight on analysts targets of AUPH, see our AUPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.03 Average Broker Recommendation 1.31 (Strong Buy)

AUPH Stock Price Chart Interactive Chart >

Price chart for AUPH

AUPH Price/Volume Stats

Current price $4.60 52-week high $24.45
Prev. close $4.65 52-week low $4.46
Day low $4.46 Volume 1,247,200
Day high $4.69 Avg. volume 2,704,488
50-day MA $6.26 Dividend yield N/A
200-day MA $9.28 Market Cap 653.71M

Aurinia Pharmaceuticals Inc (AUPH) Company Bio


Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutic] The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. The company was founded in 1993 and is based in Victoria, Canada.


AUPH Latest News Stream


Event/Time News Detail
Loading, please wait...

AUPH Latest Social Stream


Loading social stream, please wait...

View Full AUPH Social Stream

Latest AUPH News From Around the Web

Below are the latest news stories about AURINIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AUPH as an investment opportunity.

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VICTORIA, British Columbia, December 05, 2022--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that the Company’s Compensation Committee granted 2 new employees inducement stock options to purchase an aggregate of 36,220 common shares, at a per share exercise price of $5.10, the closing price of Aurinia's common stock on December 2, 2022, and an aggregate

Yahoo | December 5, 2022

Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

VICTORIA, British Columbia, November 30, 2022--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Great Britain marketing authorization of LUPKYNIS® (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus

Yahoo | November 30, 2022

Aurinia Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations

Aurinia Pharmaceuticals ( NASDAQ:AUPH ) Third Quarter 2022 Results Key Financial Results Revenue: US$55.8m (up 280...

Yahoo | November 8, 2022

H.C. Wainwright Sticks to Its Buy Rating for Aurinia Pharmaceuticals (AUPH)

H.C. Wainwright analyst Ed Arce reiterated a Buy rating on Aurinia Pharmaceuticals (AUPH - Research Report) today and set a price target of $14.00. The company's shares closed last Friday at $5.15.According to TipRanks, Arce is a 4-star analyst with an average return of 4.0% and a 35.57% success rate. Arce covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Aurinia Pharmaceuticals, and Cidara Therapeutics.In addition to H.C. Wainwright, Aurinia Pharmaceuticals also received a Buy from RBC Capital's Douglas Miehm in a report issued on November 4. However, on the same day, Oppenheimer downgraded Aurinia Pharmaceuticals (NASDAQ: AUPH) to a Hold.

Howard Kim on TipRanks | November 7, 2022

Bloom Burton Remains a Buy on Aurinia Pharmaceuticals (AUPH)

In a report released on November 3, Prasath Pandurangan from Bloom Burton maintained a Buy rating on Aurinia Pharmaceuticals (AUPH - Research Report), with a price target of $10.50. The company's shares closed last Friday at $5.15.According to TipRanks, Pandurangan is an analyst with an average return of -17.5% and a 26.42% success rate.Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $11.63, implying a 125.83% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.

Catie Powers on TipRanks | November 7, 2022

Read More 'AUPH' Stories Here

AUPH Price Returns

1-mo -8.55%
3-mo -36.64%
6-mo -60.65%
1-year -78.06%
3-year -74.01%
5-year -9.09%
YTD -79.89%
2021 65.37%
2020 -31.74%
2019 197.07%
2018 50.55%
2017 115.71%

Continue Researching AUPH

Here are a few links from around the web to help you further your research on Aurinia Pharmaceuticals Inc's stock as an investment opportunity:

Aurinia Pharmaceuticals Inc (AUPH) Stock Price | Nasdaq
Aurinia Pharmaceuticals Inc (AUPH) Stock Quote, History and News - Yahoo Finance
Aurinia Pharmaceuticals Inc (AUPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7683 seconds.